Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

Calibration of BCR–ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale

(2014) Carole Mauté et al.   CLINICAL BIOCHEMISTRY

Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR

(2014) Lawrence J. Jennings et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

(2014) H White et al.   LEUKEMIA

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

(2013) M. Ladetto et al.   BLOOD

Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale

(2013) H. E. White et al.   CLINICAL CHEMISTRY

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

What does MRD in leukemia really mean?

(2013) J M Goldman et al.   LEUKEMIA

Standardized definitions of molecular response in chronic myeloid leukemia

(2012) N C P Cross et al.   LEUKEMIA

Design and Analytic Validation of BCR-ABL1 Quantitative Reverse Transcription Polymerase Chain Reaction Assay for Monitoring Minimal Residual Disease

(2011) Lawrence J Jennings et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia

(2011) Letizia Foroni et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

(2011) Hyun-Gyung Goh et al.   LEUKEMIA & LYMPHOMA

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib

(2010) M. Sobrinho-Simoes et al.   BLOOD

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

(2010) H. E. White et al.   BLOOD

The European LeukemiaNet: achievements and perspectives

(2010) R. Hehlmann et al.   HAEMATOLOGICA

Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA

(2010) P. A. BARTLEY et al.   International Journal of Laboratory Hematology

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

(2010) D M Ross et al.   LEUKEMIA

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Standardisation of molecular monitoring for chronic myeloid leukaemia

(2009) Nicholas C.P. Cross   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

(2009) S. A. Bustin et al.   CLINICAL CHEMISTRY

Sensitive and Specific Measurement of Minimal Residual Disease in Acute Lymphoblastic Leukemia

(2009) Alexander A. Morley et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD